These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Benjamin R; Graham C; Yallop D; Jozwik A; Mirci-Danicar OC; Lucchini G; Pinner D; Jain N; Kantarjian H; Boissel N; Maus MV; Frigault MJ; Baruchel A; Mohty M; Gianella-Borradori A; Binlich F; Balandraud S; Vitry F; Thomas E; Philippe A; Fouliard S; Dupouy S; Marchiq I; Almena-Carrasco M; Ferry N; Arnould S; Konto C; Veys P; Qasim W; Lancet; 2020 Dec; 396(10266):1885-1894. PubMed ID: 33308471 [TBL] [Abstract][Full Text] [Related]
3. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Qasim W; Zhan H; Samarasinghe S; Adams S; Amrolia P; Stafford S; Butler K; Rivat C; Wright G; Somana K; Ghorashian S; Pinner D; Ahsan G; Gilmour K; Lucchini G; Inglott S; Mifsud W; Chiesa R; Peggs KS; Chan L; Farzeneh F; Thrasher AJ; Vora A; Pule M; Veys P Sci Transl Med; 2017 Jan; 9(374):. PubMed ID: 28123068 [TBL] [Abstract][Full Text] [Related]
4. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation]. Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464 [No Abstract] [Full Text] [Related]
5. [Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review]. Zuo Y; Wang J; Lu A; Jia Y; Wu J; Dong L; Chang L; Zhang L Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):115-8. PubMed ID: 27014980 [TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia. Xie L; Ma L; Liu S; Chang L; Wen F Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880 [TBL] [Abstract][Full Text] [Related]
7. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142 [TBL] [Abstract][Full Text] [Related]
8. Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy. Li Z; An N; Yang K; Meng F; Xu T; Peng X; Wen X; Li J; Song Y; Yang R; Wu T Transplant Cell Ther; 2023 Mar; 29(3):167-173. PubMed ID: 36427783 [TBL] [Abstract][Full Text] [Related]
9. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature. Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079 [TBL] [Abstract][Full Text] [Related]
10. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660 [TBL] [Abstract][Full Text] [Related]
11. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. Pan J; Tan Y; Wang G; Deng B; Ling Z; Song W; Seery S; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Yuan Y; Yan F; Tian Z; Tang K; Zhang J; Chang AH; Feng X J Clin Oncol; 2021 Oct; 39(30):3340-3351. PubMed ID: 34324392 [TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. Tan Y; Shan L; Zhao L; Deng B; Ling Z; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Tian Z; Zhang Y; Zhang J; Chang AH; Feng X; Pan J J Hematol Oncol; 2023 Apr; 16(1):34. PubMed ID: 37020231 [TBL] [Abstract][Full Text] [Related]
13. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report. Li Z; Meng F; Li J; Wu T Front Immunol; 2022; 13():931452. PubMed ID: 35903089 [TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493 [TBL] [Abstract][Full Text] [Related]
15. CD4 Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation. Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386 [TBL] [Abstract][Full Text] [Related]
18. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases. Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847 [TBL] [Abstract][Full Text] [Related]
19. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Ottaviano G; Georgiadis C; Gkazi SA; Syed F; Zhan H; Etuk A; Preece R; Chu J; Kubat A; Adams S; Veys P; Vora A; Rao K; Qasim W; Sci Transl Med; 2022 Oct; 14(668):eabq3010. PubMed ID: 36288281 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy. Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]